Ask about this productRelated genes to: FOXO1A antibody
- Gene:
- FOXO1 NIH gene
- Name:
- forkhead box O1
- Previous symbol:
- FKHR, FOXO1A
- Synonyms:
- FKH1
- Chromosome:
- 13q14.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-01-07
- Date modifiied:
- 2016-10-05
Related products to: FOXO1A antibody
Related articles to: FOXO1A antibody
- Hyperinsulinemia and insulin resistance promote acne pathogenesis through reduced Forkhead box protein O1 (FOXO1) signaling and increased mechanistic target of rapamycin (MTOR) and insulin-like growth factor-1 (IGF1) activity. While oral myo-inositol (MI) and D-chiro-inositol (DCI) supplementation may improve insulin sensitivity, evidence regarding direct pathway modulation in acne-involved skin remains limited. In this exploratory, single-arm, uncontrolled study, we sought to investigate the effects of oral MI/DCI (3.6:1 ratio) on cutaneous expression of these biomarkers in adults with acne and metabolic comorbidities (polycystic ovary syndrome or metabolic syndrome). - Source: PubMed
Publication date: 2026/04/28
Vaccaro MarioEmanuele EnzoMinoretti PiercarloGarcía-Chico CeliaKhoramipour KayvanSantos-Lozano AlejandroLista SimoneRibero Simone - Progesterone therapy is standard for fertility-preserving endometrial cancer (ECC) patients, but primary and secondary resistance limit its efficacy. Metformin (MET) combined with progesterone shows promise, yet the synergistic mechanism remains unclear. - Source: PubMed
Publication date: 2026/05/15
Hong LiangliLin RuilinZhang WeifengJiao JiweiWang ChuanWu HongrongLiao YongQiu QianchenXie QiGu Jiang - To determine the role of METTL3-mediated mA modification in hypoxic pulmonary arterial smooth muscle cells (PASMCs) over-proliferation and hypoxic pulmonary hypertension (HPH). - Source: PubMed
Publication date: 2026/05/19
Li ZhaoyangZhang YingQiu JingyiTang YinjiangYang ZhaoLei YanbinQu XiaoxuYang ChaoSun LeqiLi ZhifanSang MengmengLiang Lin - Diabetic nephropathy (DN) is a major cause of chronic kidney disease, and sensitive biomarkers of early tubular injury remain limited. Fibrinogen-like protein 2 (FGL2) has been implicated in inflammation and fibrosis, but its clinical significance and mechanistic role in DN are unclear. Serum FGL2 levels were measured in 105 patients with T2DM stratified by albuminuria and in 110 healthy controls, and its associations with metabolic parameters, renal injury, inflammation, and fibrosis were analyzed. , HK-2 cells were exposed to high glucose, and FGL2 was silenced using siRNA to assess effects on PI3K/Akt-FoxO1 signaling, cell viability, apoptosis, oxidative stress, and ECM remodeling. Pathway specificity was confirmed using a PI3K/Akt inhibitor. Serum FGL2 levels were higher in patients with T2DM than in controls and increased progressively with the severity of albuminuria. Circulating FGL2 positively correlated with glycemic indices, insulin resistance, lipid parameters, renal tubular injury markers (NGAL, KIM-1), inflammatory cytokines (TNF-α, IL-6), and fibrotic mediators (TGF-β1, CTGF). High glucose induced FGL2 expression in HK-2 cells in a dose-dependent manner. Silencing FGL2 enhanced Akt and FoxO1 phosphorylation, improved cell viability, reduced apoptosis, attenuated oxidative stress, restored antioxidant enzyme activity, and suppressed ECM-related gene and protein expression. These protective effects were reversed by PI3K/Akt inhibition. Serum FGL2 is elevated in patients with T2DM and correlates with the severity of renal injury, while mechanistically contributing to high glucose-induced tubular dysfunction the PI3K/Akt-FoxO1 signaling pathway. - Source: PubMed
Publication date: 2026/05/20
Lu Xiao GangJin HuiWang Ya PeiLi Hong BinCheng Yin Qin - Partial downregulation of pancreatic endoplasmic reticulum kinase (PERK) activity recovered insulin content in human islets exposed to glucolipotoxicity (GLT), resulting in improved insulin secretion and glucose-lowering effects in a mouse model of type 2 diabetes. We conducted this study to elucidate the beta-cell enhancing mechanisms of PERK attenuation. - Source: PubMed
Publication date: 2026/05/18
Park Yeon SooYun SoeunSim Min SeopAn Eun JinLee JinHa Eun HeeJang Jin-YoungKwon WooilHan DohyunJung Hye Seung